Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 28%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is in a good financial position with a positive outlook and potential for future growth due to its successful product offerings and shift to the pharmacy channel, but there are risks to consider such as competition and patient switching. Additionally, the company's revenue is primarily derived from the US market and their pumps and disposable infusion sets, making it essential for them to continue their expansion into other developed countries and develop new product offerings to diversify their revenue streams.

Bears say

Tandem Diabetes Care is facing multiple challenges in increasing market share and profitability, including competition from Omnipod 5, potential delays in product development, and pressure from payors and CMS. The company has a strong desire to enter the tubeless/patch market, but early signals suggest that physicians are not yet fully convinced of the benefits. Additionally, the company's decision to transition to a pay-as-you-go model and direct sales in certain markets may result in revenue headwinds in the short term, with moderate growth expected in the long term.

TNDM has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 28% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 18 analysts, TNDM has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.